Company / Operating Cash Flow per Share
Enliven Therapeutics, Inc. Operating Cash Flow per Share History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.55
FY2024
5-year range
-$10.27 / -$1.55
FY2020-FY2024
Trend
+9.8%
vs FY2023
Sector context
#136 of 212
Health Care
What the data says
At $-1.55, Enliven Therapeutics, Inc.'s operating cash flow per share ranks #136 of 212 in the Health Care sector. Improved from $-10.27 to $-1.55 over the past 2 years.
Based on SEC 10-K filings.
-1.55 in FY2024.
Improved from $-10.27 to $-1.55 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#136 of 212 in Health CareTop 64% of 212This company -$1.55 Sector average $5.28
▼
-129.5% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow per share increased 9.8% year-over-year.
- Ranks #136 out of 212 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$1.55 | +9.8% |
| FY2023 | -$1.72 | +83.2% |
| FY2022 | -$10.27 | -375.5% |
| FY2021 | -$2.16 | +19.6% |
| FY2020 | -$2.69 | +91.4% |
| FY2019 | -$31.14 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026